AOD-9604

AOD-9604 — short for "Anti-Obesity Drug 9604" — is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH). It reproduces amino acids 177 to 191 of the growth hormone molecule and adds a single tyrosine residue at the N-terminus for stability, giving a 16-amino-acid chain stabilized by a disulfide bond between its two cysteine residues.

The peptide was developed in the late 1990s by Metabolic Pharmaceuticals, an Australian biotechnology company, based on research at Monash University into which part of the growth hormone molecule is responsible for its fat-burning activity. Scientists had long observed that growth hormone accelerates the breakdown of stored fat, but full-length hGH also raises blood sugar, promotes tissue growth, and increases insulin-like growth factor 1 (IGF-1) — effects that make it unsuitable as a simple weight-loss agent.

The central idea behind AOD-9604 was molecular editing: isolate the small "lipolytic domain" of growth hormone that drives fat metabolism, and leave behind the parts responsible for the hormone's growth-promoting and diabetogenic actions. In theory, this would produce a targeted fat-loss compound without the metabolic baggage of full growth hormone.

To understand where AOD-9604 sits in the wider landscape of these compounds, it helps to first understand what peptides are and how short amino-acid chains can act as signaling molecules. AOD-9604 is a textbook example of fragment-based peptide design — taking a natural protein and keeping only the functional piece.

This article is for educational purposes only. AOD-9604 is a research peptide and is not an approved medicine for human use.

The proposed mechanism of AOD-9604 centers on two complementary effects on fat cells (adipocytes): stimulating lipolysis (the breakdown of stored triglycerides into free fatty acids) and inhibiting lipogenesis (the formation and storage of new fat). This dual action mirrors the way full-length growth hormone influences fat tissue, but in a more restricted way.

In laboratory studies, AOD-9604 appeared to increase the metabolic activity of fat cells and shift them toward energy release rather than storage. Some rodent research suggested it may enhance the expression of enzymes involved in fat oxidation and interact with pathways connected to beta-3 adrenergic signaling, which governs fat mobilization. Importantly, this activity was observed even in animals lacking a functional growth hormone receptor, implying that AOD-9604 may act through a mechanism partly distinct from classic growth hormone signaling.

The most clinically attractive feature reported in preclinical work was what AOD-9604 did not do. Unlike full growth hormone, it did not meaningfully raise IGF-1 levels, did not promote cell proliferation, and did not impair insulin sensitivity or glucose tolerance in the animal models studied. This selectivity is the entire rationale for the molecule: fat-loss signaling without the growth and blood-sugar consequences of the parent hormone.

It is worth being precise about the strength of this evidence. Much of the mechanistic understanding comes from cell-culture and rodent experiments rather than detailed human physiology studies. The peptide's behavior in the human body — including how efficiently it reaches and acts on fat tissue — is far less well characterized than its behavior in animal models. Compounds that work elegantly in a petri dish or a mouse frequently behave differently in people, a recurring theme across the peptide field.

The most encouraging data for AOD-9604 come from preclinical research. In studies of obese mice, chronic treatment with the peptide reduced body weight gain and fat mass and increased fat metabolism, with effects that in some experiments were comparable to those of full-length growth hormone — but without the accompanying rise in IGF-1 or disruption of glucose handling.

Researchers also reported that AOD-9604 influenced lipid metabolism through mechanisms that persisted in animals engineered to lack certain adrenergic receptors, suggesting the peptide engages more than one pathway to affect fat tissue. These findings, published in endocrinology journals in the early 2000s, generated significant interest and drove the compound toward human testing.

However, a crucial distinction must be made between preclinical promise and clinical proof. Rodent obesity models are useful for identifying candidate mechanisms, but they routinely overstate how well a compound will perform in humans. Metabolic differences between species, differences in dosing relative to body size, and the far more complex regulation of human body weight all contribute to this translation gap.

In short, the animal evidence supports a plausible fat-loss mechanism, but it does not establish that AOD-9604 produces meaningful fat loss in people. That question could only be answered by human trials — and, as the next section explains, the human data told a more sobering story. Readers evaluating any fat-loss peptide should apply the same evidence hierarchy: preclinical signal is a starting point, not a conclusion.

AOD-9604 progressed further than many research peptides: it was tested in genuine human clinical trials for obesity. Early-phase studies established that the peptide was generally well tolerated when administered to overweight and obese adults, with a safety profile that did not raise major red flags in the doses examined.

The decisive test came in a larger placebo-controlled Phase IIb obesity trial. In this study, participants receiving AOD-9604 did not lose significantly more weight than participants receiving placebo. The primary efficacy endpoint — meaningful reduction in body weight — was not met. Following these disappointing results, the developer discontinued AOD-9604 as an anti-obesity drug candidate.

This is the single most important fact for anyone evaluating AOD-9604 today: the human clinical evidence for weight loss is negative, not positive. The compound that showed promise in mice did not translate into a clinically effective obesity treatment for people. Marketing claims that present AOD-9604 as a validated fat-loss drug misrepresent the trial record.

It is important not to overstate the negative conclusion either. The trial evaluated specific doses, delivery methods, and durations; a failed obesity endpoint does not necessarily rule out any biological activity, and it does not close the door on other potential applications being explored in different research contexts. But for the flagship use case — as a stand-alone weight-loss medicine — the human data did not support approval.

Anyone considering this peptide should weigh that history carefully and discuss it with a qualified clinician. A candidate that reaches Phase II and fails its primary endpoint is a candidate whose central claim has been tested and not confirmed. Please review our medical disclaimer before acting on any information in this guide.

After the obesity program ended, research interest in AOD-9604 shifted toward other potential applications, primarily in the areas of joint and cartilage health and regenerative research. These represent early-stage investigations rather than established uses.

Some animal studies have examined intra-articular (into-the-joint) injection of AOD-9604 in osteoarthritis models, sometimes combined with hyaluronic acid, reporting improvements in cartilage regeneration markers. This has led to interest in the peptide as a possible adjunct in joint-repair research, an area where other peptides such as BPC-157 and TB-500 are also being studied. It is essential to stress that this evidence is preclinical and preliminary; it does not demonstrate a proven benefit for osteoarthritis or joint injuries in humans.

Separately, AOD-9604 obtained self-affirmed Generally Recognized As Safe (GRAS) status in the United States for certain limited, non-drug applications. GRAS is a food-ingredient safety designation and is often misunderstood: it reflects a safety determination for a narrow use context, not an endorsement of efficacy, and it is emphatically not the same as FDA approval of a drug for treating obesity or any other condition.

The realistic summary is that AOD-9604's story after its obesity failure is one of exploratory, unproven directions. The joint-health research is genuinely interesting from a scientific standpoint, but it remains firmly in the experimental phase. None of these secondary applications should be presented to consumers as validated treatments.

Because AOD-9604 is not an approved medicine, there is no officially sanctioned dosing protocol, no regulated product, and no established standard of care. Any dosing information reflects protocols used in research settings or reported anecdotally in the peptide community — not medical guidance.

In its clinical development, AOD-9604 was studied primarily as a subcutaneous injection and, in some formulations, as an oral or transmucosal preparation. Injectable protocols described in the research and community literature have typically involved microgram-to-milligram-range daily doses, often administered in a fasted state on the rationale that lower circulating insulin may favor fat mobilization. It is important to recognize that these regimens are not backed by an approved label or by convincing human efficacy data.

Peptides that require reconstitution from a lyophilized powder demand careful, sterile handling and accurate measurement. Readers researching these practicalities may find a reconstitution calculator useful for understanding the calculations involved, though this is provided strictly for educational context.

The responsible position is unambiguous: no dose of an unapproved research peptide can be recommended for human use here. Anyone contemplating AOD-9604 should consult a qualified healthcare professional who can assess individual risk, and should understand that self-administration of research chemicals carries real and poorly quantified risks.

In the human clinical trials conducted during its development, AOD-9604 was reported to be generally well tolerated, with a safety and side-effect profile broadly comparable to placebo in the doses and durations tested. A published safety review of the peptide concluded that it did not produce the metabolic disturbances associated with full growth hormone, such as clinically significant changes in IGF-1 or glucose metabolism.

That relatively clean trial-safety record, however, comes with major caveats. First, safety data were generated under controlled conditions using pharmaceutical-grade material, defined doses, and medical supervision — conditions that do not apply to research peptides bought online and self-administered. Second, the trials were not designed to detect rare or long-term effects, and there is essentially no data on years-long use. "Well tolerated in a short trial" is not the same as "safe for indefinite personal use."

A further, often underestimated risk lies in product quality. Research peptides sold outside the regulated pharmaceutical supply chain vary enormously in purity, may be underdosed or mislabeled, and can contain contaminants or bacterial endotoxins. Injecting an improperly manufactured or non-sterile product introduces risks of infection and adverse reactions that have nothing to do with the peptide's intrinsic pharmacology. Common general risks of injectable peptides include injection-site reactions such as redness, swelling, or irritation.

No peptide should be described as free of side effects, and AOD-9604 is no exception. The honest assessment is that its clinical-trial safety looked favorable, but the real-world safety of unregulated self-administration is unknown and cannot be assumed. Individuals with any medical condition, and anyone taking other medications, should seek professional medical advice before considering it.

AOD-9604 is not approved as a drug by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or comparable regulators. Its obesity development program did not lead to marketing authorization, and it has no approved therapeutic indication.

In the United States, it is generally sold and labeled as a research chemical or "for research use only," a designation that explicitly excludes human consumption. The self-affirmed GRAS status noted earlier applies only to specific limited uses and does not authorize AOD-9604 as a medicine or a general dietary supplement ingredient for weight loss. Legal status also varies considerably between countries, and importing or possessing research peptides may be restricted or prohibited in some jurisdictions.

For athletes, an additional rule applies. AOD-9604 is a growth-hormone-derived fragment, and the World Anti-Doping Agency (WADA) prohibits growth hormone fragments. Athletes subject to anti-doping testing should treat AOD-9604 as a banned substance and avoid it entirely; a positive test can end a competitive career.

The practical takeaway is that AOD-9604 occupies a regulatory gray zone: legal to sell as a research reagent in many places, but not approved, not quality-controlled as a medicine, and not sanctioned for the fat-loss purpose it is most often marketed for. Consumers should be skeptical of any vendor presenting it as a legitimate, approved weight-loss product. Legal status changes over time and by region — verify current local regulations before making any decisions.

Placing AOD-9604 in context helps clarify what it is and isn't. It is frequently grouped with growth-hormone-related peptides such as CJC-1295 and other growth hormone secretagogues, but the mechanisms differ. Secretagogues stimulate the body's own release of growth hormone (and consequently IGF-1), whereas AOD-9604 was specifically designed to reproduce only the fat-metabolizing fragment of growth hormone without raising IGF-1.

In the weight-loss arena, the most important comparison is with the GLP-1 receptor agonists such as semaglutide and tirzepatide. These are a fundamentally different class of drugs, and the contrast is stark: GLP-1 medicines are FDA-approved and have demonstrated 15–22% average body-weight reduction in large randomized trials, whereas AOD-9604 failed to beat placebo in its Phase II obesity study. On the strength of human evidence, the two are not remotely comparable as fat-loss agents.

Some users explore combining peptides, a practice discussed in our guide to peptide stacking. Stacking amplifies uncertainty rather than reducing it: combining unapproved compounds compounds the unknowns around efficacy, safety, and interactions, and there is no reliable human evidence that any AOD-9604-based stack produces meaningful fat loss.

The bottom line is that AOD-9604 is an interesting example of rational peptide design whose central promise did not survive human testing. For readers whose goal is evidence-based fat loss, approved therapies backed by robust clinical trials sit in an entirely different tier — and any decision should be made with a qualified healthcare professional.